Page last updated: 2024-11-03

((2-n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1h-inden-5-yl)oxy)acetic acid and Disease Models, Animal

((2-n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1h-inden-5-yl)oxy)acetic acid has been researched along with Disease Models, Animal in 2 studies

((2-n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy)acetic acid: an anion channel blocker

Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Okada-Ogawa, A1
Nakaya, Y1
Imamura, Y1
Kobayashi, M1
Shinoda, M1
Kita, K1
Sessle, BJ1
Iwata, K1
Huang, YJ1
Lee, KH1
Murphy, L1
Garraway, SM1
Grau, JW1

Other Studies

2 other studies available for ((2-n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1h-inden-5-yl)oxy)acetic acid and Disease Models, Animal

ArticleYear
Involvement of medullary GABAergic system in extraterritorial neuropathic pain mechanisms associated with inferior alveolar nerve transection.
    Experimental neurology, 2015, Volume: 267

    Topics: Acetates; Action Potentials; Animals; Disease Models, Animal; Extracellular Signal-Regulated MAP Kin

2015
Acute spinal cord injury (SCI) transforms how GABA affects nociceptive sensitization.
    Experimental neurology, 2016, Volume: 285, Issue:Pt A

    Topics: Acetates; Analysis of Variance; Animals; Bicuculline; Bumetanide; Capsaicin; Disease Models, Animal;

2016